Gene expression markers for colorectal cancer prognosis
Granted: October 4, 2011
Patent Number:
8029995
A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject.
Gene expression markers for colorectal cancer prognosis
Granted: September 27, 2011
Patent Number:
8026060
A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject.
Gene expression profiling of EGFR positive cancer
Granted: August 30, 2011
Patent Number:
8008003
The present invention concerns prognostic markers associated with EGFR positive cancer. In particular, the invention concerns prognostic methods based on the molecular characterization of gene expression in paraffin-embedded, fixed tissue samples of EGFR-expressing cancer, which allow a physician to predict whether a patient is likely to respond well to treatment with an EGFR inhibitor.
Expression profile algorithm and test for cancer prognosis
Granted: May 10, 2011
Patent Number:
7939261
The present invention provides a noninvasive, quantitative test for prognosis determination in cancer patients. The test relies on measurements of the tumor levels of certain messenger RNAs (mRNAs). These mRNA levels are inserted into a polynomial formula (algorithm) that yields a numerical recurrence score, which indicates recurrence risk.
Predicting response to chemotherapy using gene expression markers
Granted: April 19, 2011
Patent Number:
7930104
The present invention provides gene expression information useful for predicting whether a cancer patient is likely to have a beneficial response to treatment with chemotherapy, comprising measuring, in a biological sample comprising a breast tumor sample obtained from the patient, the expression levels of gene subsets to obtain a risk score associated with a likelihood of a beneficial response to chemotherapy, wherein the score comprises at least one of the following variables: (i)…
Genes involved estrogen metabolism
Granted: February 15, 2011
Patent Number:
7888019
The invention concerns genes that have been identified as being involved in estrogen metabolism, and are useful as diagnostic, prognostic and/or predictive markers in cancer. In particular, the invention concerns genes the tumor expression levels of which are useful in the diagnosis of cancers associated with estrogen metabolism, and/or in the prognosis of clinical outcome and/or prediction of drug response of such cancers.
Gene expression markers for predicting response to chemotherapy
Granted: January 18, 2011
Patent Number:
7871769
The present invention provides sets of genes the expression of which is important in the prognosis of cancer. In particular, the invention provides gene expression information useful for predicting whether cancer patients are likely to have a beneficial treatment response to chemotherapy FHIT; MTA1; ErbB4; FUS; BBC3; IGF1R; CD9; TP53BP1; MUC1; IGFBP5; rhoC; RALBP1; STAT3; ERK1; SGCB; DHPS; MGMT; CRIP2; ErbB3; RAP1GDS1; CCND1; PRKCD; Hepsin; AK055699; ZNF38; SEMA3F; COL1A1; BAG1; AKT1;…
Gene expression profiling in biopsied tumor tissues
Granted: December 28, 2010
Patent Number:
7858304
The invention concerns sensitive methods to measure mRNA levels in biopsied tumor tissues, including archived paraffin-embedded biopsy material. The invention also concerns breast cancer gene sets important in the diagnosis and treatment of breast cancer, and methods for assigning the most optimal treatment options to breast cancer patient based upon knowledge derived from gene expression studies.
Gene expression profiling in biopsied tumor tissues
Granted: November 23, 2010
Patent Number:
7838224
The invention concerns sensitive methods to measure mRNA levels in biopsied tumor tissues, including archived paraffin-embedded biopsy material. The invention also concerns breast cancer gene sets important in the diagnosis and treatment of breast cancer, and methods for assigning the most optimal treatment options to breast cancer patient based upon knowledge derived from gene expression studies.
Use of intronic RNA to measure gene expression
Granted: August 3, 2010
Patent Number:
7767391
The invention is based on the use of intronic RNA in monitoring gene expression. Accordingly, the present invention concerns methods of gene expression profiling using intronic RNA, the expression of which correlates with the expression of corresponding exonic RNA, and diagnostic and prognostic methods based on the results of such gene expression studies.
Prediction of likelihood of cancer recurrence
Granted: May 25, 2010
Patent Number:
7723033
The present invention provides gene sets, the expression of which is important in the diagnosis and/or prognosis of cancer, in particular of breast cancer.
Gene expression markers for colorectal cancer prognosis
Granted: April 13, 2010
Patent Number:
7695913
A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject.
Molecular indicators of breast cancer prognosis and prediction of treatment response
Granted: November 24, 2009
Patent Number:
7622251
The present invention relates to quantitative molecular indicators that can guide clinical decisions in breast cancer, such as estrogen receptor (ESR1)-positive, lymph node-negative breast cancer. In particular, the invention concerns certain genes, the varied expression of which indicates the likelihood of recurrence of surgically resected breast cancer in patients who are not treated with a therapeutic agent in the adjuvant setting. In addition, the invention concerns the use of…
Method for quantitative PCR data analysis system (QDAS)
Granted: September 8, 2009
Patent Number:
7587279
This invention provides a method for the quantitation and quality assurance of QPCR data. In particular, the invention provides a method for extracting data curves from a QPCR assay, estimating the shape and characteristics of an amplification curve and producing a quality score metric. The invention also provides a robust method for calculating a threshold cycle (CT) value and classifying the status of the QPCR results.
Gene expression markers for breast cancer prognosis
Granted: August 4, 2009
Patent Number:
7569345
The present invention provides gene sets the expression of which is important in the diagnosis and/or prognosis of breast cancer.
Expression profile algorithm and test for cancer prognosis
Granted: April 28, 2009
Patent Number:
7526387
The present invention provides a noninvasive, quantitative test for prognosis determination in cancer patients. The test relies on measurements of the tumor levels of certain messenger RNAs (mRNAs). These mRNA levels are inserted into a polynomial formula (algorithm) that yields a numerical recurrence score, which indicates recurrence risk.
Gene expression profiling in biopsied tumor tissues
Granted: July 25, 2006
Patent Number:
7081340
The invention concerns sensitive methods to measure mRNA levels in biopsied tumor tissues, including archived paraffin-embedded biopsy material. Th invention also concerns breast cancer gene sets important in the diagnosis and treatment of breast cancer, and methods for assigning the most optimal treatment options to breast cancer patient based upon knowledge derived from gene expression studies.
Prediction of likelihood of cancer recurrence
Granted: June 6, 2006
Patent Number:
7056674
The present invention provides gene sets the expression of which is important in the diagnosis and/or prognosis of cancer, in particular of breast cancer.
